Impact of combined therapy of mesenchymal stem cells and sitagliptin on a metabolic syndrome rat model.

Yossra AhmedZeinab Y AliMona A MohamedLaila A RashedEhsan K Mohamed

Published in: Journal of diabetes and metabolic disorders (2021)

Combined therapy of MSCs and sitagliptin can efficiently ameliorate the insulin resistance and promote the regeneration of hepatocytes in the metabolic syndrome rat model.

Keyphrases

metabolic syndrome
insulin resistance
mesenchymal stem cells
umbilical cord
uric acid
adipose tissue
high fat diet
type diabetes
bone marrow
cell therapy
cardiovascular risk factors
skeletal muscle
cardiovascular disease
high fat diet induced
liver injury
drug induced